| Sunday, September 28, 2003 |
|
Surprise, surprise
:
Remember the campus television show I was bitching about because I was not asked to participate? Well, as the turning gears of irony would have it, the creator of the show is none other than MY OWN BOYFRIEND. Yea, I...
vividblurry ::: 2:19:03 PM ::: |
|
Cingular goes down
:
Word is going around that there is something grievously wrong with Cingular's GSM cellular network, with lots of customers (concentrated mainly in the Midwest) not being able to get service. Read [Via MobileTracker]...
Gizmodo ::: 1:42:09 PM ::: |
|
Sobig Worm Attacking RBL Lists?
:
Slashdot ::: 10:12:46 AM ::: |
|
Have We Shot Ourselves in the Foot?
:
Have our successes fueled an already serious public health problem? See how HIV myth and complacency complicates our battle against HIV....
AIDS/HIV ::: 8:43:01 AM ::: |
| Saturday, September 27, 2003 |
|
Major Problems with Cingular Network
:
Slashdot ::: 11:11:49 PM ::: |
|
Confessions of a Spam King
:
Free registration may be required.
1. MEET THE SPAMMER
''Click here,'' says my spamming mentor. Hovering over my chair, he points to the computer screen. ''Now click on that file of e-mail addresses there.'' I have been invited by a master for an education in spamming, the practice of blasting millions of unsolicited e-mail messages into the Internet in order to advertise everything from loans with easy terms to women of easy virtue.
''Let's go online and download some software,'' says my guide. His name is Richard Colbert. On the Rokso, or Register of Known Spam Operations (a kind of Most Wanted List for the Internet posted on an antispam Web site called spamhaus.org), Colbert is described plainly: ''Nonstop scam spammer, kicked off so many hosts and I.S.P.s'' -- or Internet service providers -- ''it's hard to count.''
(Marc Erickson)
Lockergnome's Technology News ::: 10:40:38 PM ::: |
| Friday, September 26, 2003 |
|
Worms sent via IM pose serious, growing threat
:
Researchers at conference stress vulnerabilities
InfoWorld: Security ::: 3:24:07 PM ::: |
|
Get A Degree In Spamming At "Spam University"
:
"Welcome to Spam University, the world's top-rated educational institution for the growing spam industry. Are you tired of your dead-end job? Want to make some big-time cash without actually working? Earn the money you deserve in the exciting and fast-growing spam industry. At Spam University, you'll earn while you learn. Our hands-on curriculum will teach you time-proven spamming techniques: Everything you need to make a name for yourself in the fast-paced spam industry.
Unfortunately, the admissions requirements are quite stringent.
Attended at least four years of elementary school.
No more than three felony convictions
The ability to count to 20 without removing your socks
Toilet-trained
No more than 36 tattoos
Familiarity with computers (i.e., you've seen one in a store or on TV)
Apply early, and apply often. We here at Pocket PC Thoughts have worked out a deal to get you up to 20% off of your admission price at Spam University. Just reply to this thread with your Name, Credit Card Number and Expiration Date, your email address and the email addresses of your 25 closest relatives and friends so we can contact them in case of an emergency.
Pocket PC Thoughts ::: 2:00:00 PM ::: |
|
Reuters Extends Enterprise Instant Messaging
:
Vendors look to third-party IM management software to link disparate offerings.
eWEEK Technology News ::: 12:19:48 PM ::: |
| Thursday, September 25, 2003 |
|
Low-Dose Indinavir in Combination With Low-Dose Ritonavir: Steady-State Pharmacokinetics and Long-Term Clinical Outcome Follow-Up
:
The use of combination therapy with antiretroviral drugs such as indinavir (IDV) has resulted in long-term suppression of HIV replication, which has been correlated to a decrease in morbidity and mortality for HIV-infected patients. HIV Medicine Medscape Hiv-Aids Headlines ::: 9:00:00 AM ::: |
|
Early Virologic Failure With Tenofovir + Lamivudine + Abacavir: An Expert Interview With Joel Gallant, MD
:
Joel Gallant, MD, of the John Hopkins School of Medicine, discusses the GlaxoSmithKline ESS30009 trial, which compared 3TC-ABC plus TDF to 3TC-ABC plus efavirenz in antiretroviral-naive subjects. Medscape HIV-AIDS Medscape Hiv-Aids Headlines ::: 9:00:00 AM ::: |
| Home |
| Photo Album |
| News |
| Apartment Swap Info |
| About 'SamAntix' |
 |
|
|
|
|